Compare VYX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | ARDX |
|---|---|---|
| Founded | 1881 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 975.9M |
| IPO Year | 1996 | 2014 |
| Metric | VYX | ARDX |
|---|---|---|
| Price | $8.56 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $13.67 | ★ $15.14 |
| AVG Volume (30 Days) | 2.4M | ★ 4.2M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,156,000,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.29 | N/A |
| 52 Week Low | $6.02 | $3.68 |
| 52 Week High | $13.50 | $8.40 |
| Indicator | VYX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 30.25 |
| Support Level | $7.37 | N/A |
| Resistance Level | $10.20 | $6.47 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 57.45 | 20.51 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.